French study tracks Real-World success of combo therapy for stomach cancer
NCT ID NCT06504615
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study observes 208 adults in France with advanced or metastatic stomach, esophageal, or gastroesophageal junction cancer who are receiving nivolumab combined with chemotherapy as their first treatment. Researchers will track how long patients live and how their disease progresses in real-life settings, not in a controlled trial. The goal is to understand the treatment's effectiveness outside of clinical trials.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL ADENOCARCINOMA (EAC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Kappa Santé
Paris, France
-
Local Institution - 0001
Paris, 75002, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can AI-Guided home training boost recovery from gastric cancer surgery?
- Can a new drug combo shrink Hard-to-Treat tumors?
- Can an AI eye guide surgeons to safer, faster cancer removal?
- Can immunotherapy outperform chemo after stomach cancer surgery?
- Could a smartphone program supervised by AI boost recovery after stomach cancer surgery?
- Can a triple punch of immunotherapy and chemoradiation wipe out esophageal tumors before surgery?